Neuraxpharm Buys Into Cannabidiol Business
Acquires Switzerland’s STU, Specializing In CBD Consumer Products
Neuraxpharm has entered the cannabidiol arena by striking a deal to buy Switzerland’s STU, a developer and distributor of natural cannabidiol consumer products.
You may also be interested in...
Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.
Neuraxpharm has appointed Jörg Gärtner to lead its business in Switzerland, as the CNS specialist prepares to roll out its medical cannabis portfolio in the region.
CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.